ABSTRACT
No disponible
No disponible
Subject(s)
Male , Middle Aged , Humans , Hemangiosarcoma/pathology , Scalp/pathology , Skin Neoplasms/pathology , Neoplasms, Radiation-Induced/pathologyABSTRACT
El cáncer de mama es la primera causa de muerte por cáncer en la mujer y la principal causa de muerte en la mujer entre los 40 y 44 años. En la actualidad se están consiguiendo importantes logros en su curación, debido a destacados avances diagnósticos y terapéuticos, así como a los programas de screenning, que hace que cada vez el diagnóstico se haga en las fases más tempranas de la enfermedad. Su tratamiento requiere una actuación multidisciplinar en la que participan cirujanos, oncólogos radioterápicos y médicos. En este capítulo, los autores realizan una puesta al día del papel de la radioterapia en el tratamiento del cáncer de mama en las diferentes etapas de la enfermedad (AU)
Subject(s)
Female , Humans , Breast Neoplasms/radiotherapy , Carcinoma, Intraductal, Noninfiltrating/radiotherapy , Mastectomy , Breast Neoplasms/classification , Neoplasm Staging/methods , Neoplasm Recurrence, Local/radiotherapyABSTRACT
OBJECTIVE: To present the results of a retrospective study which was conducted to analyze the utility of palliative radiotherapy in advanced bladder cancer and to evaluate the results of the different fractionation regimens in relation to the response rate and its duration, overall survival and side effects. METHODS: During a 10-year period, 56 patients with locally advanced bladder cancer received palliative external radiotherapy for the symptoms arising from their condition. The following fractionation schedules were mainly used: conventional irradiation with 40-60 Gy in 22-23 fractions in 20 cases and a low dose of 30 Gy in 10 fractions in 23. Other fractionation modalities were used in 6 patients. Eight patients received radiotherapy for symptomatic relief of pain from bony metastasis. RESULTS: 28 patients (50%) achieved complete remission of the initial symptoms and 15 (26.8%) showed a partial remission. The mean duration of response was 4 months (range 1-108). The overall uncorrected survival rate was 26.7% at one year (15 patients), 12.5% at three years (7 patients) and 7.1% at five years (4 patients), for a mean survival of 7.5 months (range 1-109). CONCLUSION: Radiotherapy is effective in the management of symptoms, specially hematuria, in patients with advanced carcinoma of the urinary bladder. Short fractionation regimens that achieve the same therapeutic results are preferred since visits to the hospital or long hospitalization can be avoided, thereby improving patient quality of life.
